Amygdala Neuroscience

OverviewSuggest Edit

Amygdala Neuroscience is a company that develops therapies designed to cure addiction. Its therapies include a selective ALDH2 inhibitor that prevents a surge in dopamine levels associated craving without changes to basal dopamine, enabling patients to quit and get rid of addiction to drugs, alcohol, and smoking.
TypePrivate
Founded2015
Websiteamygns.com

Key People/Management at Amygdala Neuroscience

Peter Strumph

Peter Strumph

Chief Executive Officer and Founder, Director
Ivan Diamond

Ivan Diamond

Chief Scientific Officer and Founder, Director
Mack Mitchell

Mack Mitchell

MD, Chief Medical Officer
Adrienne MacMillan

Adrienne MacMillan

Chief Financial Officer and Founder
Brent Blackburn

Brent Blackburn

Chief Development Officer and Founder
Lou Lange

Lou Lange

Executive Chairman and Founder, Director
Show more

Amygdala Neuroscience Financials and Metrics

Summary Metrics

Founding Date

2015

Amygdala Neuroscience total Funding

$7 m

Amygdala Neuroscience latest funding size

$5.60 m

Time since last funding

3 months ago

Amygdala Neuroscience investors

Amygdala Neuroscience's latest funding round in November 2019 was reported to be $5.6 m. In total, Amygdala Neuroscience has raised $7 m
Show all financial metrics

Amygdala Neuroscience Online and Social Media Presence

Embed Graph

Amygdala Neuroscience Frequently Asked Questions

  • When was Amygdala Neuroscience founded?

    Amygdala Neuroscience was founded in 2015.

  • Who are Amygdala Neuroscience key executives?

    Amygdala Neuroscience's key executives are Peter Strumph, Ivan Diamond and Mack Mitchell.

  • Who are Amygdala Neuroscience competitors?

    Competitors of Amygdala Neuroscience include Acticor Biotech, Genoa Pharmaceuticals and Palatin Technologies.